Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pasireotide + cabergoline
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Pasireotide + cabergoline is a combination of two pituitary-targeted agents used primarily in the management of Cushing's disease and other pituitary disorders. Pasireotide is a second-generation somatostatin analog that binds with high affinity to somatostatin receptors, especially SSTR1, SSTR2, SSTR3, and SSTR5, leading to inhibition of ACTH secretion and reduced cortisol production. Cabergoline is an ergot-derived dopamine receptor agonist with high selectivity for D2 receptors; it suppresses prolactin secretion and can also inhibit ACTH release from corticotroph tumors. The combination has been shown to normalize cortisol levels in patients with Cushing's disease who are not adequately controlled by monotherapy. Both drugs are generally well tolerated but require monitoring for specific adverse effects such as hyperglycemia (pasireotide) and cardiac valvulopathy (cabergoline)[2][3][4][5][6].
- Brand names
- SigniforDostinex
- Other names
- pasireotide + cabergoline
02
Targets
DRD2 (Dopamine D2 Receptor)SSTR1 (Somatostatin Receptor Type 1)SSTR5 (Somatostatin receptor 5)SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)
Beyond the preview
Go deeper on pasireotide + cabergoline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pasireotide + cabergoline.